139 related articles for article (PubMed ID: 11751017)
1. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
Gelperina SE; Khalansky AS; Skidan IN; Smirnova ZS; Bobruskin AI; Severin SE; Turowski B; Zanella FE; Kreuter J
Toxicol Lett; 2002 Jan; 126(2):131-41. PubMed ID: 11751017
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
Ambruosi A; Khalansky AS; Yamamoto H; Gelperina SE; Begley DJ; Kreuter J
J Drug Target; 2006 Feb; 14(2):97-105. PubMed ID: 16608736
[TBL] [Abstract][Full Text] [Related]
3. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
Ambruosi A; Gelperina S; Khalansky A; Tanski S; Theisen A; Kreuter J
J Microencapsul; 2006 Aug; 23(5):582-92. PubMed ID: 16980278
[TBL] [Abstract][Full Text] [Related]
4. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Kreuter J; Gelperina S
Toxicol Lett; 2008 Apr; 178(1):9-19. PubMed ID: 18374523
[TBL] [Abstract][Full Text] [Related]
5. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
[TBL] [Abstract][Full Text] [Related]
6. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects.
Hekmatara T; Bernreuther C; Khalansky AS; Theisen A; Weissenberger J; Matschke J; Gelperina S; Kreuter J; Glatzel M
Clin Neuropathol; 2009; 28(3):153-64. PubMed ID: 19537130
[TBL] [Abstract][Full Text] [Related]
7. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats.
Ambruosi A; Yamamoto H; Kreuter J
J Drug Target; 2005 Dec; 13(10):535-42. PubMed ID: 16390814
[TBL] [Abstract][Full Text] [Related]
8. Use of nanoparticles for cerebral cancer.
Kreuter J; Gelperina S
Tumori; 2008; 94(2):271-7. PubMed ID: 18564616
[TBL] [Abstract][Full Text] [Related]
9. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Wohlfart S; Khalansky AS; Bernreuther C; Michaelis M; Cinatl J; Glatzel M; Kreuter J
Int J Pharm; 2011 Aug; 415(1-2):244-51. PubMed ID: 21641983
[TBL] [Abstract][Full Text] [Related]
10. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.
Gulyaev AE; Gelperina SE; Skidan IN; Antropov AS; Kivman GY; Kreuter J
Pharm Res; 1999 Oct; 16(10):1564-9. PubMed ID: 10554098
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.
Steiniger SC; Kreuter J; Khalansky AS; Skidan IN; Bobruskin AI; Smirnova ZS; Severin SE; Uhl R; Kock M; Geiger KD; Gelperina SE
Int J Cancer; 2004 May; 109(5):759-67. PubMed ID: 14999786
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
Petri B; Bootz A; Khalansky A; Hekmatara T; Müller R; Uhl R; Kreuter J; Gelperina S
J Control Release; 2007 Jan; 117(1):51-8. PubMed ID: 17150277
[TBL] [Abstract][Full Text] [Related]
13. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma.
Pereverzeva E; Treschalin I; Treschalin M; Arantseva D; Ermolenko Y; Kumskova N; Maksimenko O; Balabanyan V; Kreuter J; Gelperina S
Int J Pharm; 2019 Jan; 554():161-178. PubMed ID: 30414476
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and apoptotic gene expression in an in vitro model of the blood-brain barrier following exposure to poly(butylcyanoacrylate) nanoparticles.
Hall AM; Hemmer R; Spaulding R; Wetzel HN; Curcio J; Sabel BA; Henrich-Noack P; Pixley S; Hopkins T; Boyce RL; Schultheis PJ; Haik KL
J Drug Target; 2016 Aug; 24(7):635-44. PubMed ID: 26707984
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.
De Juan BS; Von Briesen H; Gelperina SE; Kreuter J
J Drug Target; 2006 Nov; 14(9):614-22. PubMed ID: 17090397
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumour.
Reddy LH; Sharma RK; Murthy RS
J Drug Target; 2004; 12(7):443-51. PubMed ID: 15621669
[TBL] [Abstract][Full Text] [Related]
18. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.
Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J
Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
